The invention provides bupropion analogue compounds capable of inhibiting the reuptake of one or more monoamines. The compounds may selectively bind to one or more monoamine transporters, including those for dopamine, norepinephrine, and serotonin. Such compounds may be used to treat conditions that are responsive to inhibition of the reuptake of monoamines, including addiction, depression, and obesity.
The invention provides bupropion analogue compounds capable of inhibiting the reuptake of one or more monoamines. The compounds may selectively bind to one or more monoamine transporters, including those for dopamine, norepinephrine, and serotonin. Such compounds may be used to treat conditions that are responsive to inhibition of the reuptake of monoamines, including addiction, depression, and obesity.
Two Enantiocomplementary Ephedrine Dehydrogenases from <i>Arthrobacter</i> sp. TS-15 with Broad Substrate Specificity
作者:Tarek Shanati、Cameron Lockie、Lilian Beloti、Gideon Grogan、Marion B. Ansorge-Schumacher
DOI:10.1021/acscatal.9b00621
日期:2019.7.5
The recently identified pseudoephedrine and ephedrine dehydrogenases (PseDH and EDH, respectively) from Arthrobacter sp. TS-15 are NADH-dependent members of the oxidoreductase superfamily of short-chain dehydrogenases/reductases (SDRs). They are specific for the enantioselective oxidation of (+)-(S) N-(pseudo)ephedrine and (−)-(R) N-(pseudo)ephedrine, respectively. Anti-Prelog stereospecific PseDH
[EN] MONOAMINE REUPTAKE INHIBITORS<br/>[FR] INHIBITEURS DE LA RECAPTURE DES MONOAMINES
申请人:RES TRIANGLE INST
公开号:WO2010121022A1
公开(公告)日:2010-10-21
The invention provides bupropion analogue compounds capable of inhibiting the reuptake of one or more monoamines. The compounds may selectively bind to one or more monoamine transporters, including those for dopamine, norepinephrine, and serotonin. Such compounds may be used to treat conditions that are responsive to inhibition of the reuptake of monoamines, including addiction, depression, and obesity.